Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$354.76M
Close$
$-7.91
165.9% downside
Current Fair Value
165.9% downsideOvervalued by 165.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $354.76 Million |
|---|---|
| Enterprise Value | $376.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 0.94 |
| Outstanding Shares | 29,090,000 |
Return
| Return on Equity | -62.56% |
|---|---|
| Return on Assets | -21.30% |
| Return on Invested Capital | -22.04% |
Valuation & Multiples
| P/E Ratio | -5.06 |
|---|---|
| PEG | -74.17 |
| Price to Sales | 6.0 |
| Price to Book Ratio | 4.0 |
| Enterprise Value to Revenue | 5.78 |
| Enterprise Value to EBIT | -7.05 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$16.76 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.77
Average shareholder expectationRevenue Estimate
$15.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5219▲ 14.06% |
|---|---|
| Total Calls | 38,900▲ 1.57% |
| Total Puts | 20,300▲ 39.04% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 94.75%▲ 2.55% |
|---|---|
| Total Invested | $401.71M▲ 18.81% |
| Investors Holding | 127▼ 8.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly